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Fibroblast growth factors (FGFs) that signal through FGF receptors (FGFRs) regulate a broad spectrum of biological functions,
including cellular proliferation, survival, migration, and diﬀerentiation. The FGF signal pathways are the RAS/MAP kinase
pathway, PI3 kinase/AKT pathway, and PLCγ pathway, among which the RAS/MAP kinase pathway is known to be predominant.
SeveralstudieshaverecentlyimplicatedtheinvitrobiologicalfunctionsofFGFsfortissueregeneration.However,toobtainoptimal
outcomes in vivo, it is important to enhance the half-life of FGFs and their biological stability. Future applications of FGFs are
expected when the biological functions of FGFs are potentiated through the appropriate use of delivery systems and scaﬀolds. This
review will introduce the biology and cellular functions of FGFs and deal with the biomaterials based delivery systems and their
current applications forthe regeneration of tissues,including skin,blood vessel,muscle, adipose, tendon/ligament, cartilage, bone,
tooth, and nerve tissues.
1.Introduction
Tissue engineering, with signiﬁcant research inputs over
the last decades, has emerged as a potential tool to regen-
erate damaged and diseased tissues [1]. As one of the
key components in tissue engineering approach, growth
factors provide chemical cues to stem cells, regulating
their biological responses and tissue diﬀerentiation. While
the basic biological functions of growth factors and their
endogenic roles in tissue development and repair process
have relatively been well studied, the use of growth factors in
tissue engineering regime has recently gained great interest.
Growth factors are a potential agent to target speciﬁc
tissue reactions because of their regulatory roles in cellular
functions, including adhesion, proliferation, migration, and
diﬀerentiation in the epithelium, bone, and soft connective
tissues and nerves.
Fibroblast growth factor (FGF) is a representative growth
factor which has shown the potential eﬀects on the repair
and regeneration of tissues [2–6]. It was originally identiﬁed
as a protein capable of promoting ﬁbroblast proliferation
and is now known to comprise 22 members. FGFs exert
multiple functions through the binding into and activation
of ﬁbroblast growth factor receptors (FGFRs), and the main
signaling through the stimulation of FGFRs is the RAS/MAP
kinase pathway. With their potential biological functions,
FGFs have been utilized for the regeneration of damaged
tissues, including skin, blood vessel, muscle, adipose, ten-
don/ligament, cartilage, bone, tooth, and nerve. Then, the
prospective source of FGF for the tissue regeneration is used
with recombinant human FGF family. In fact, many previous
studies administered the FGFs directly to the wound sites,
like other growth factors. However, free-FGFs are readily
degradable in vivo, leading to loss of biological activity and2 Journal of Tissue Engineering
functions [7–9]. To gain satisfactory performance, FGFs are
adsorbed onto or encapsulated within materials to secure
biological activity in a sustained and controllable manner.
Although many types of materials have been developed to
carry FGFs and elicit their therapeutic eﬃcacy in vitro and
in vivo, more sustained, controlled, and targeted delivering
system still remain a challenge.
Here, we review the cellular biology of FGFs and their
functions in cell proliferation, migration, diﬀerentiation,
and angiogenesis and address the current development
of biomaterials-based delivery systems of FGFs and their
applications for tissue regeneration, including skin, blood
vessel, muscle, adipose, tendon/ligament, cartilage, bone,
tooth, and nerve.
2.Biology ofFGF
FGF, which was ﬁrst discovered in pituitary extracts in 1973,
is widely expressed in cells and tissues. Acidic FGF (FGF1)
andbasicFGF(FGF2)wereoriginallyisolatedfromthebrain
and pituitary gland as growth factors for ﬁbroblasts. Since
then,atleast22distinctFGFshavebeenidentiﬁedorisolated.
FGFs have been found in both vertebrates and inverte-
brates. Many FGF genes have been identiﬁed in vertebrates,
including ten FGFs in zebraﬁsh (FGF2–4, 6, 8, 10, 17a,
17b, 18, 24), six in Xenopus (FGF2–4, 8–10), 13 in chickens
(FGF1–4, 8–10, 12, 13, 16, 18–20), 22 in mice (FGF1–18,
20–23) and humans (FGF1–14, 16–23), whereas only three
Drosophila FGF genes and two Caenorhabditis elegans FGF
genesha v ebeenobserv edinin v ert ebrat es[10].HumanFGFs
contain 22 members: FGF1, FGF2, FGF3 (INT2), FGF4,
FGF5, FGF6, FGF7 (KGF), FGF8 (AIGF), FGF9, FGF10,
FGF11, FGF12, FGF13, FGF14, FGF16, FGF17, FGF18,
FGF19, FGF20, FGF21, FGF22, and FGF23 [11].
The FGF family comprises 23 members, although there
are only 18 FGFR ligands. Four family members do not
bind with FGFR as FGF homologous factors (FGF11, FGF12,
FGF13,andFGF14)andaremorecorrectlyreferredtoasFGF
homologous factors. In addition, there is no human FGF15
gene; the gene orthologous to mouse FGF15 is FGF19 [12].
Byphylogeneticanalysis,thehumanFGFgenefamilycan
be divided into seven subfamilies: FGF1, FGF4, FGF7, FGF8,
FGF9, FGF11, and FGF19 (Figure 1). The FGF1, FGF4,
FGF7, FGF8, FGF9, FGF11, and FGF19 subfamilies comprise
FGF1 and 2, FGF4, 5, and 6, FGF3, 7, 10, and 22, FGF8,
17, and 18, FGF9, 16, and 20, FGF11, 12, 13, and 14, and
FGF19, 21, and 23, respectively. In contrast to phylogenetic
analysis, gene location analysis indicates that the human FGF
gene family can be divided into six subfamilies: FGF1/2/5,
FGF3/4/6/19/21/23, FGF7/10/22, FGF8/17/18, FGF9/16/20,
and FGF11/12/13/14. Members of the FGF8, FGF9, and
FGF11 subfamilies are similar to those of the FGF7/10/22,
FGF8/17/18, FGF9/16/20, and FGF11/12/13/14 subfamilies
in the gene location analysis [13].
The molecular weight of FGFs in vertebrates varies from
17 to 34kDa, while the Drosophila FGF is 84kDa. All
members of the family share a conserved sequence of 120
amino acids that show 16%–65% sequence identity [14].
FGFs have various biological functions both in vivo and
in vitro, including roles in mitogenesis, cellular migration,
diﬀerentiation, angiogenesis, and wound healing.
FGFs exert their physiological roles through binding
FGFR and regulate developmental pathways, controlling
events such as mesoderm patterning in the early embryo
through development of multiple organ systems. The mam-
malian FGF family is composed of 18 ligands that elicit
their actions through four highly conserved transmembrane
tyrosine kinase receptors (FGFR1, FGFR2, FGFR3, and
FGFR4) [12]. Four FGFRs have been identiﬁed in humans
and mice and encode receptor tyrosine kinases (ca. 800
amino acids) that contain an extracellular ligand-binding
domain with three immunoglobulin domains (I, II, and
III), a transmembrane domain, and a split intracellular
tyrosine kinase domain [15]. FGFRs are expressed on many
diﬀerent cell types and regulate key cell behaviors, such as
proliferation, diﬀerentiation, and survival, which make FGF
signaling susceptible to subversion by cancer cells. Unlike
other growth factors, FGFs act in concert with heparin or
heparan sulfate proteoglycan (HSPG) to activate FGFRs and
induce the pleiotropic responses that lead to a variety of
cellular responses induced by this large family of growth
factors [14].
Recent studies of FGF or FGFR have focused on muta-
tionsrelatedtodisease.SeveralgermlineFGFmutationshave
been identiﬁed in human disease, including loss-of-function
mutations, and gain-of-function mutations. For instance,
loss-of-function in FGF3 is involved with hereditary deaf-
ness, leading to total inner ear agenesis in humans [16].
Degradation of FGF8 by loss-of-function leads to kallmann’s
syndrome (KAL1), a developmental disorder characterized
by anosmia and hypogonadism [17]. FGF10 loss-of-function
causes lacrimo-auditory-dento-digital (LADD) syndrome,
which is characterized by hearing loss, dental anomalies,
and lacrimal and salivary gland hypoplasia [18]. Gain-
of-function mutations in FGF23 have been identiﬁed in
hypophosphataemic rickets [19].
Table 1 summarizes the location, receptor, and therapeu-
tic application of the FGF family.
3.FGFSignaling
FGFs act as signal molecules that bind and activate FGFRs.
Activated FGFRs mediate signaling by recruiting speciﬁc
molecules that bind to phosphorylated tyrosine at the
cytosolic part of the receptor, triggering a number of
signaling pathways leading to speciﬁc cellular responses.
These then serve as docking sites for the recruitment of
SH2 (Src homology-2) or PTB (phosphotyrosine binding)
domains of adaptors docking proteins or signaling enzymes.
Signaling complexes are formed and recruited to the active
receptors resulting in a cascade of phosphorylation events
[20]. The best understood pathways are the RAS/MAP
kinasepathway,PI3kinase/AKTpathway,andPLCγ pathway.
Figure 2 schematically describes the three pathways of the
FGF signal, the RAS/MAP kinase pathway, PI3 kinase/AKT
pathway, and PLCγ pathway.Journal of Tissue Engineering 3
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Figure 1: Phylogenetic tree of human FGF family [13]. Human FGF gene family can be divided into seven subfamilies containing two to
four members each. Branch lengths are proportional to the evolutionary distance between each gene.
3.1. RAS/MAP Kinase Pathway. Mitogen-activated protein
(MAP) kinases are serine/threonine-speciﬁc protein kinases
that respond to extracellular stimuli (mitogens) and regulate
various cellular activities such as gene expression, mitosis,
diﬀerentiation, and cell survival/apoptosis [21]. c-Jun N-
terminal kinase (JNK), extracellular signal regulated kinase
(ERK), and p38 mitogen-activated kinase are examples of
eﬀectors MAP kinase [22]. Interestingly, the activation of
ERK 1/2 and p38 in response to FGF has been observed in
all cell types, while the activities of other signal transduction
pathways vary depending on the cell type.
To date, the main pathway of the FGF signal is the
RAS/MAP kinase pathway, which contains many signaling
proteins. A key event in the FGF signaling pathway is
phosphorylation of the tyrosine residues of the docking
protein, ﬁbroblast growth factor receptor substrate 2α
(FRS2α), which provides new binding sites for direct or
indirect recruitment of proteins that are responsible for
both activation and attenuation of signaling [23, 24]. FRS2α
recruits a complex consisting of an adaptor protein, the
guanine nucleotide exchange factor 2 (GRB2), the son
of sevenless (SOS), the tyrosine phosphatase (SHP2), and
the docking protein, GRB2-associated binding protein 1
(GAB1). Formation of the FRS2 signaling complex results in
activationofRAS/MAPkinase[25]aswellasPI3kinase/AKT
pathways [26]. The RAS-MAP kinase pathway has been
implicated in cell growth and diﬀerentiation in many studies
[11].
Lax et al. [24] showed that FGF signals induce a
MAP kinase mediated negative feedback loop that causes
threonine phosphorylation of FRS2a, leading to a reduction
of its tyrosine phosphorylation and decreased recruitment of
GRB2. Receptor tyrosine kinases also induce negative signals
via activation of the sprouty proteins that inhibit the recruit-
ment of GRB2-SOS complexes to FRS2 and the receptor and
attenuate the RAS-MAP kinase pathway. Members of the
Sef and MAP kinase phosphatase families are other negative
modulators of FGF signaling, while XFLRT3, a member of a
leucine-rich-repeat transmembrane protein family, is a novel
positive modulator. Expression of XFLRT3 is induced by
FGF and down-regulated after inhibition of FGF signaling
[27]. Thus, FGF signaling is modulated by both positive and
negative mechanisms, and subtle modulations in the signal
areimportantdeterminantsofthebiologicalresponseduring
development.
3.2. PI3 Kinase/AKT Pathway. Similar to the RAS/MAP
kinase pathway, the phosphoinositide 3 (PI3) kinase/AKT
pathway is initiated by forming an FRS2 signaling complex.
Next, GAB1 protein links activated FGF receptors with PI3
kinase. GAB1 consists of a pleckstrin homology domain, a
proline-rich region, and multiple tyrosine phosphorylation
sites that serve as binding sites for the SH2 domains. The
p110 catalytic subunit of PI3 kinase is in a complex with an
adaptor protein (p85) that has two SH2 domains; thus, p85
binds to phosphorylated tyrosine residues in GAB1 adaptor
protein. Phosphoinositide-dependent kinase and the anti-
apoptotic protein kinase AKT are activated downstream of
the PI3 kinase [26].
ThePI3kinase/AKTpathwayisimplicatedincellsurvival
and cell fate determination, as well as the PI3 kinase/aPKC4 Journal of Tissue Engineering
Table 1: Physiological eﬀects of the human FGF gene.
Gene Location Receptor Therapeutic application Ref.
FGF1 5q31.3 FGFR 1b, 1c, 2b, 2c, 3b, 3c, 4 Cardiovascular disease [32]
FGF2 4q27 FGFR 1b, 1c, 2c, 3c, 4 Cardiovascular disease, cancer [33–36]
FGF3 11q13.3 FGFR 1b, 2b Not established
FGF4 11q13.3 FGFR 1c, 2c, 3c, 4 Stable angina [37]
FGF5 4q21.21 FGFR 1c Hair growth [38]
FGF6 12p13.32 FGFR 1c, 2c, 4 Not established
FGF7 15q21.2 FGFR 2b Oral mucositis [39]
FGF8 10q24.32 FGFR 3c, 4 Not established
FGF9 13q12.11 FGFR 2c, 3b, 3c, 4 Not established
FGF10 5p12 FGFR 1b, 2b Not established
FGF11 17p13.1 Intracytoplasmic Not established
FGF12 3q28 Not identiﬁed Not established
FGF13 Xq26.3 Not identiﬁed Not established
FGF14 13q33.1 Not identiﬁed Not established
FGF16 Xq21.1 FGFR 4 Not established
FGF17 8p21.3 FGFR 2c, 3c, 4 Not established
FGF18 5q35.1 FGFR 2c, 3c, 4 Osteoarthritis, cartilage [40]
FGF19 11q13.3 FGFR 4 Diabetes [41]
FGF20 8p22 Not identiﬁed Parkinson’s disease [42]
FGF21 19q13.32 Not identiﬁed Diabetes [43]
FGF22 19p13.3 FGFR 2b Not established
FGF23 12p13.32 FGFR 3c Hypophosplataemia [44]
signaling cascade in cell polarity control [11]. B¨ ottcher et al.
[27] showed that GAB1 is required for stimulation of the
AKT pathway by FGF.
3.3. PLCγ Pathway. One of the target molecules for activated
FGFR is phospholipase C gamma (PLCγ), which binds to the
phosphorylated Tyr-766 of the receptor and then becomes
tyrosine phosphorylation of PLCγ, resulting in PLCγ activa-
tion. Activated PLCγ hydrolyzes phosphatidylinositol, gener-
ating inositol triphosphate (IP3) and diacylglycerol (DAG)
[28]. IP3 is a cellular second messenger that facilitates
the release of calcium from the endoplasmic reticulum.
Increased levels of calcium in the cytosol and DAG together
activate protein kinase C (PKC). The physiological relevance
of this pathway is not obvious since its disruption does not
abolish either mitogenesis [29]o rc e l ld i ﬀerentiation [30].
However, some data indicate that it may be necessary for
adhesion, at least in some cell types [31].
4.Biological FunctionsofFGFs
As stated above, FGFs exert their physiological roles by
binding to high aﬃnity tyrosine kinase FGFRs on the surface
of the target cell. Therefore, the function of FGFs depends
on the FGF signal pathway between the FGF family and
FGFRs.ManystudieshavereportedthatFGFshavefunctions
such as cell proliferation, migration, diﬀerentiation, and
angiogenesis in various cells and tissues. Table 2 summarizes
the function of FGFs.
4.1. Cell Proliferation. Cell proliferation by FGFs has been
reported in many cell types, including endothelial cells, stem
cells, and epithelial cells. FGF1 is a proliferative factor for
human preadipocytes that may be important to the overall
regulation of human adipogenesis [45]. In addition, FGF1
leadstoanincreaseintheproliferationofIEC-6,Caco-2,and
HT-29 celllines withFGF2and FGF7 [46]. FGF2induces cell
proliferation after ﬂia-speciﬁc gene transfer in mice [47]a n d
stimulates the proliferation and survival of neuroepithelial
cells isolated from the telencephalon and mesencephelon of
E10 mice [48]. FGF4 knockout mouse embryos experience
postimplantation lethality owing to the necessity of FGF4
fortrophoblastproliferation[49].FGF7(calledhumanKGF)
is related to the epithelial cell growth [50]. FGF10 play a
role in the pathogenesis of prostate cancer via facilitation
of epithelial cell proliferation [51]. FGF18 has also been
shown to stimulate the proliferation of cultured mouse
primary osteoblasts, osteoblastic MC3T3-E1 cells, primary
chondrocytes, and prechondrocytic ATDC5 cells, although
it inhibited the diﬀerentiation and matrix synthesis of these
cells [52]. Interestingly, some FGFs stimulate proliferation of
c a n c e rc e l l sa sw e l la sn o r m a lc e l l s .
4.2. Cell Migration. Cell migration is a central process in the
development and maintenance of multicellular organisms.
Tissue formation during embryonic development, wound
healing, and immune responses all require the orchestrated
movement of cells in particular directions to speciﬁc loca-
tions. Cells often migrate in response to and toward speciﬁc
external signals in a process known as chemotaxis. CellJournal of Tissue Engineering 5
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Figure 2: FGF signal pathway. FGFs stimulate tyrosine phosphorylation of the docking protein FRS, followed by forming the GRB2-
SHP2-GAB-1 complex resulting in activation of RAS-MAP kinase pathway and PI3 kinase/AKT pathway. In PLCγ pathway, activated PLCγ
hydrolyzes phosphatidylinositol, generating IP3 and DAG and results in the activation of PKC. FRS2: ﬁbroblast growth factor receptor
substrate 2, GRB: guanine nucleotide exchange factor, SOS: son of sevenless, RAS: monomeric G-protein, RAF: kinase, MEK: kinase, MKP1:
MAP kinase phosphatase, PIP2: phosphatidylinositol (4,5)-bisphosphate, IP3: inositol triphosphate, DAG: diacylglycerol, PKC: protein
kinase C.
migration of FGFs varies with subfamilies. Apparently, both
FGF1 and FGF2 play important roles in the migration
of cochlear ganglion neurons in mice [53]. FGF2 induces
cell migration after ﬂia-speciﬁc gene transfer in mice [47]
and stimulates cell migration of mouse embryonic limb
myogenic cells such as FGF4 [54]. FGF7 is known to stim-
ulate migration and plasminogen activity (PA) of normal
human keratinocytes [55]. Similar to FGF2, FGF8 is a potent
chemoattractant in the migration of mesencephalic neural
crest cells [56].
4.3. Cell Diﬀerentiation. In developmental biology, cellular
diﬀerentiation is the process by which a less specialized cell
becomes a more specialized cell type. Diﬀerentiation occurs
numerous times during the development of multicellular
organisms as they change from a single zygote to a complex
systemof tissues and celltypes. Diﬀerentiation is common in
adults as well. Speciﬁcally, adult stem cells divide and create
fully-diﬀerentiated daughter cells during tissue repair and
normal cell turnover. Diﬀerentiation dramatically changes
the size, shape, membrane potential, metabolic activity, and
responsiveness of a cell to signals.
Cell diﬀerentiation of FGFs also varies with subfam-
ilies. FGF1 and FGF2 play important roles in the initial
diﬀerentiation of cochlear ganglion neurons in mice [29].
Moreover, FGF2 stimulates the diﬀerentiation of neuroep-
ithelial cells into mature neurons and glia [48]. FGF7 is
essential for the morphogenesis of suprabasal keratinocytes
and establishment of the normal program of keratinocyte
diﬀerentiation [57]. Exogenous FGF20 stimulates the diﬀer-
entiation of monkey stem cells into dopaminergic neurons
after treatment in vitro [42].
4.4. Angiogenesis. Angiogenesis is the process of the forma-
tion of new blood vessels from pre-existing vessels. This pro-
cess plays a key role in various physiological and pathological6 Journal of Tissue Engineering
Table 2: Functions of ﬁbroblast growth factors.
Function Subfamily related to the function Target cell Ref.
Cell proliferation
FGF1, FGF2 Preadipocyte [45–48]
Endothelial cell, epithelial cell,
ﬁbroblast cell, neural stem cell
FGF4 Trophoblast stem cell [49]
FGF7, FGF10 Epithelial cell [50, 51]
FGF18 Osteoblast, chondrocytes, osteoclast [52]
Cell migration
FGF2 Astrocyte, myogenic cell [47, 54]
FGF4 Myogenic cell [54]
FGF7 Epithelial cell, keratinocyte [55]
FGF8 Neural crest cell [56]
Cell diﬀerentiation
FGF1, FGF2 Neuroepithelial [48, 52]
FGF7 Keratinocyte [57]
FGF20 Monkey stem cell [42]
Angiogenesis FGF1, FGF2 Endothelial cell [61]
conditions such as embryonic development, wound repair,
inﬂammation, and tumor growth [58]. Angiogenesis is
a multistep process that begins with the degradation of
the basement membrane by activated endothelial cells that
migrate and proliferate, leading to the formation of solid
endothelial cell sprouts into the stromal space. Next, vascular
loops are formed and capillary tubes develop with the
formationoftightjunctionsanddepositionofnewbasement
membrane [59].
Numerous inducers of angiogenesis have been identiﬁed,
including members of the vascular endothelial growth factor
(VEGF) family, angiopoietins, transforming growth factor-
alpha and -beta (TGF-alpha and beta), platelet-derived
growth factor (PDGF), tumor necrosis factor-alpha (TNF-
alpha), interleukins, chemokines, and members of the
ﬁbroblast growth factor (FGF) family [60]. However, only a
limited number of the 22 members of the FGF family have
been investigated for their angiogenic potential in vitro and
in vivo [61]. The angiogenic properties of FGF1 and FGF2
are well known. Speciﬁcally, FGF1 and FGF2 induce the
promotion of endothelial cell proliferation and the physical
organization of endothelial cells into tube-like structures.
Thus, they promote angiogenesis. FGF1 and FGF2 are more
potent angiogenic factors than vascular endothelial growth
factor (VEGF) or platelet-derived growth factor (PDGF).
FGF4 also has angiogenic properties.
5. DeliverySystems for FGFs
Due to their speciﬁc biological functions and roles, FGFs
have the potential for application to induce the regeneration
of a wide spectrum of tissues, including skin, blood vessel,
muscle, adipose, tendon/ligament, cartilage, bone, tooth,
and nerve tissues. Indeed, many previous studies have
evaluated the administration of FGFs directly to the sites of
wounds, similar to that of other growth factors. However,
when free FGF solutions are injected in vivo, they rapidly
lose their biological functional activity, primarily due to
diﬀusional loss and/or enzymatic inactivation/degradation
[7–9]. Therefore, to gain satisfactory performance, a large
amount of FGFs with a continuous dose for the determined
period is required.
Conversely, when FGFs are adsorbed onto or encapsu-
lated within materials, their degradation risk can be largely
protected while securing the biological activity. Therefore,
to make full use of the FGFs, it is essential to develop
appropriate materials and substrates to contain and deliver
them to defective regions, after which allowing their release
at a controllable and sustainable rate. A wide range of
biomaterials including synthetic and natural polymers and
even tissue matrices have been studied as candidate materials
to carry FGFs and elicit their therapeutic eﬃcacy in vitro
and/or in vivo.
While their functional activity has been demonstrated
in diﬀerent types of cells in vitro and/or target tissues in
vivo, there have been relatively few, if any, reports address-
ing the delivery mechanism. In this part, we review the
applications of FGFs in concert with medical materials for
tissue regeneration. Speciﬁc targets include skin, cartilage,
bone, blood vessel, muscle, tendon/ligament, and nerve. The
materials are developed to speciﬁcally conjugate with FGFs
or encapsulate within the structure and are engineered in
the form of hydrogels or porous scaﬀolds or nano- and
microparticulates.
5.1. Porous Scaﬀolds. Generally, the most common scaﬀold
materials range from polymers (synthetic or natural) and
ceramicstotheircomposites,whichcanbechosendepending
on the target tissues of concern. Many natural polymers
such as collagen, alginate, ﬁbrin, silk, chitosan, and gly-
cosaminoglycans (GAGs) are biologically well deﬁned, tissue
compatible, and degradable; therefore, they are regarded as
feasible materials for the intake of growth factors within the
structures [62]. Such polymers are easily engineered intoJournal of Tissue Engineering 7
porous scaﬀolds by dissolution in water-based solutions and
subsequent freeze-drying [63, 64]. Because they dissolve well
in water, the incorporation of FGFs is possible during the
fabrication step. When incorporated within the structure,
growth factors are released through the scaﬀold when they
come into contact with the ﬂuid. In most cases, bulk
diﬀusionisthedominantmethodofreleasinggrowthfactors,
which is led by water permeation and can be accelerated by
collapse of the polymer network.
Due to their comprising a class of proteins or polysac-
charides, natural polymers contain a large number of ionic
groups. Apart from chitosan, which is highly positively
charged, all of the other proteins mentioned above preserve
a large number of negatively charged groups [65]. Therefore,
depending on their charge characteristics (basic or acidic),
FGFs can form charge-charge interactions with natural
polymers. In such cases, the FGF-incorporated scaﬀolds
show sustained and long-term delivery of FGFs if their
structure is maintained without collapse [65, 66]. More
speciﬁc biochemical interactions between the FGFs and
naturalproteinsarefavoredinmaintenanceofthestabilityof
FGFs, which can be exploited by utilizing some binding sites
ofFGFs,suchastheheparinbindingsite[8,67,68].Collagen
scaﬀolds mixed with heparin hold FGF2 within the structure
better than scaﬀolds without heparin, which is beneﬁcial for
long-term FGF delivery [68]. Hydrogel-type scaﬀolds that
absorb a high level of water within their pore structure and
are mechanically meta-stable gel matrices will be discussed
separately in the following section.
Synthetic polymers primarily those that are
degradable, such as poly(lactic acid), poly(glycolic acid),
poly(caprolactone), and their copolymers have also been
well developed into porous scaﬀolds by many possible
processing routes [69]. Unlike natural polymers, this class of
polymers can be dissolved in nonaqueous organic solvents
that would otherwise melt at elevated temperatures, and
most growth factors, including FGFs, are very susceptible
to degradation when incorporated during the scaﬀold
processing stages. Therefore, surface modiﬁcation of the
scaﬀolds is recommended to carry the growth factors.
Through chemical treatment of the surface of synthetic
polymers such as amination or carboxylation, growth factors
can be covalently coupled via the formation of an amide
linkage [70, 71]. However, in such cases, growth factors
are only on the scaﬀold surface, which limits the continual
biological action of FGFs and long-term targeting while
inﬂuencing the initial adhesive reactions of cells.
Apart from the polymer groups, bioceramics are promis-
ing candidate materials for grafting defects of hard tissues,
such as bones and teeth [72–79]. Many publications and
clinical trials have already demonstrated the high perfor-
mance of some bioceramics including calcium phosphates
and bioactive glasses/glass ceramics [73, 77, 79]. Therefore,
for hard tissue regeneration, there is a potential need to use
bioceramics in concert with growth factors including FGFs,
leading to some pioneering studies on the incorporation of
FGFs within bone grafts [80, 81]. However, most currently
applicable bioceramics can only be obtained following
heat treatment (generally above a thousand degree), which
limits the direct loading of growth factors within the
scaﬀolds. Nevertheless, some unique properties such as
granular morphology (grain boundaries), surface charges,
crystallography, and micropores are known to signiﬁcantly
alter the adsorption of proteins and their release behaviors
[82–85], which suggests the possible manipulation of FGFs
on bioceramic scaﬀolds that is diﬀerent from the case in
polymers.
One promising form of bioceramics is self-setting or
hardening cements, such as calcium phosphate cements that
quickly harden when they come in contact with water-
based solutions and are easily moldable and applicable in
an injectable type [78, 115]. While their applications in hard
tissue reconstruction have a long history, the need for using
this class of material for drug delivery including growth
factors has emerged recently. FGF-incorporating cements
that target bones and teeth are considered to hold great
promise; however, additional studies evaluating their use are
necessary [116].
5.2. Hydrogels. N a t u r a lp o l y m e r ss u c ha sc o l l a g e n ,g e l a t i n ,
ﬁbrin, and glycosaminoglycans are the most commonly used
hydrogels for tissue regeneration and drug delivery. These
hydrogels largely mimic the native extracellular matrices
(ECMs)oftissues,andcellsrecognizethehydrogelmolecules
in a manner similar to the recognition that occurs under
in vivo conditions [117]. When FGFs are loaded within
the hydrogels of natural polymers, they play a role in
controlling cell processes, such as cell division, migration,
and diﬀerentiation. Because the growth factors easily bind
to ECM components such as heparan sulfate proteoglycans
and ﬁbronectin [118, 119], these compounds are often
combined with hydrogel matrices. The bound growth factors
are secured within the hydrogel matrices until released by an
enzymatic reaction or hydrolytic cleavage.
Collagen hydrogels form a ﬁbrillar network, which is also
degradable enzymatically through the action of collagenase.
The binding of growth factors to the collagen ﬁbrillar
network is largely noncovalent. However, recent studies have
reported the recombinant fusion of growth factors into well-
known collagen binding sequences such as the sequence
from collagenase, von Willerbrand factor, or ﬁbronectin
[120]. Gelatin is a denatured form of collagen that has
been investigated as a good candidate carrier of FGFs
[121]. Depending on the charge characteristics (acidic or
basic) and biodegradability of gelatin, the release proﬁle of
FGFs can vary greatly. In the case of FGF2, acidic gelatin
hydrogel with low water content was better at stimulating
angiogenesis [122]. Fibrin hydrogel can be formed through
the spontaneous polymerization of ﬁbrinogen in the pres-
ence of thrombin protease. Thus, growth factors can be
incorporated into the ﬁbrin network during the coagulation
[123]. The FGF2 noncovalently bound to the ﬁbrin network
was able to provide growth factor-speciﬁc bioactivity, such
as enhancing endothelial cell proliferation [124]. GAGs are
strongly anionic polymer hydrogels that can absorb a large
amount of water while preserving good mechanical integrity.
Similar to collagen, GAGs bind growth factors noncovalently8 Journal of Tissue Engineering
Table 3: Tissue applications of ﬁbroblast growth factors.
Target tissue Subfamily
of FGF Materials/carriers In vivo/in
vitro Animal/cell Functions/eﬀects Ref
Skin FGF2 Gelatin microsphere In vivo Guinea pig Wound healing [86]
FGF2 Chitosan hydrogel In vivo Mouse Wound healing [87]
Vessels FGF2 Gelatin hydrogel In vivo Mouse Vascularization [88]
FGF2 Heparinized collagen In vitro Endothelial
cell Cell growth [68]
FGF2 Heparinized PLGA scaﬀold In vivo/In
vitro Mouse Vascularization [88]
FGF2 PLGA microsphere-alginate
porous scaﬀold In vivo Rat Capillary penetration,
vascularization [89]
Muscle FGF2 PLGA nanoparticle In vivo/In
vitro Mouse Arteriogenesis [90]
Adipose FGF2 Matrigel In vivo Mouse Adipogenesis [91]
FGF2 Matrigel-gelatin microspheres In vivo Mouse Adipogenesis [92]
FGF2 Gelatin microsphere-collagen
scaﬀold In vivo Mouse/rabbit Adipose regeneration [93, 94]
Tendon/
Ligament FGF2 Gelatin-PLA scaﬀold In vivo Rabbit ACL and bone regeneration [95]
FGF2 Silk/PLGA scaﬀold In vitro BMSCs Proliferation, diﬀerentiation [96]
Cartilage FGF2 PGA scaﬀold In vitro Chondrocyte Dediﬀerentiation [97]
FGF2 Collagen sponge In vivo Mouse Cartilage regeneration [98]
FGF2 Gelatin microsphere-polymer
scaﬀold
In vivo/In
vitro Mouse Chondrogenesis,
vascularization [99]
FGF2 Collagen-PGLA-PLCL scaﬀold In vivo Chondrocyte Tracheal regeneration [100]
FGF2 Collagen-PLLA scaﬀold In vitro Chondrocyte Proliferation [101]
Bone FGF1 Hydroxyapatite-ﬁbrin scaﬀold In vivo Rat Osteogenic markers, bone
regeneration [81]
FGF2 Hyaluronate scaﬀold In vitro BMSCs Osteogenic markers,
mineralization [102]
FGF2 Gelatin hydrogel In vivo Rabbit Mineralization, bone
regeneration [103]
FGF2 Hydroxyapatite porous granules In vitro MC3T3-E1 Cell proliferation, osteoblast
diﬀerentiation [104]
FGF2 Collagen-bioactive glass In vivo Rat Bone regeneration [105]
FGF2 Ti based metals-matrigel In vivo/In
vitro Rat Bone regeneration [106]
FGF2 Hydroxyapatite/collagen
scaﬀold In vivo Rabbit Bone regeneration, cartilage
regeneration [107]
FGF2 Ti implant-melatonin In vivo Rat Osseointegration [108]
Dental FGF2 Gelatin microsphere In vivo Dog Periodontal regeneration [109]
FGF2 Tricalcium phosphate In vivo Dog Alveolar tissue regeneration [110]
Nerve FGF1 pHEMA-MMA In vivo Rat Axonal regeneration [111]
FGF2 Polyamide nanoﬁber scaﬀold In vitro Astrocyte Neurite outgrowth [5]
FGF2 Porous PLA scaﬀold In vivo Rat Cell migration, angiogenesis [112]
FGF2 Polyethylene glycol In vivo Rat Spinal cord injury repair [113]
FGF2 Polymer tube channel In vivo/In
vitro Rat Peripheral nerve regeneration [90]
FGF2 Gelatin hydrogel In vivo Guinea pig Facial nerve functions [114]Journal of Tissue Engineering 9
but very stably and then further release them through the
enzymatic cleavage reaction [125]. The structure of GAGs
is often modiﬁed to provide sites of covalent binding for
biomecules, such as adhesive proteins and growth factors.
Synthetic hydrogel polymers can be formed with var-
ious compositions, including poly(ethylene glycol) (PEG),
poly(vinyl alcohol) (PVA), and poly(hydroxyethyl methacry-
late) (PHEMA) [126]. During preparation of the synthetic
hydrogels, various target binding domains or cleavage
domains such as MMP-cleavable sequences and growth fac-
tor binding ligands can be introduced, and these ultimately
play a role in covalently linking growth factors such as FGFs
and further allowing cleavage of the network to release FGFs
[127]. When compared to the natural polymer hydrogels,
which have limited properties to control, the development
of synthetic polymer hydrogels to retain the functional and
some cell/tissue responsive properties are now increasing
rapidly. Indeed, cell responsive functional groups can be
tuned to deliver speciﬁc molecules including FGFs, and the
mechanical and degradation properties can be manipulated
to be responsive to surrounding conditions, such as pH,
temperature, light, and mechanical load [7, 128]. As one
example, a PEG hydrogel system was engineered to be
crosslinked through a photoreaction, during which time
physical properties such as the degree of swelling could be
modulated [7]. The release of FGF2 from the hydrogel was
highly dependent on the crosslinking density, which was
mediated by the swelling ability.
5.3. Nano- and Micro-Particulates. When compared to the
structured porous scaﬀolds or hydrogels, particulate forms
with sizes at the nano- (tens to hundreds of nanome-
ters) and micron-scale (a few micrometers) have gained
interest for specialized delivery of growth factors, requiring
a system to be delivered through the blood stream and
oral administration, and within intracellular compartments
[129–132]. Many diﬀerent formulations of natural and
synthetic polymeric materials for this purpose have been
reported, and these primarily include liposomes, micelles,
dendrimers, microspheres, nanospheres, and nanoshells
[132]. The common process in production of those partic-
ulates requires the formation of droplets within solutions
that were conditioned to disperse individual particles while
preserving the morphological (spherical) integrity. The size
and composition of the particulates are easily controllable,
which ultimately determines the release proﬁle of growth
factors.
As described in the previous section, natural polymers
suchasgelatinandcollagenarepossiblecandidatesforinsitu
encapsulation of FGFs during the formation of particulates,
where the charge interaction of natural polymers with FGFs
must be considered. Similarly, synthetic polymers can be
exploited in the form of nanoshells (or nanocapsules),
in which hydrophobic polymers comprise an outer shell
that surrounds an inner water-based portion that contains
hydrophilic growth factors [89, 133]. Depending on the
polymer composition and outer shell thickness, the release
proﬁle of growth factors can be controlled. Due to their
sizes being far greater or less than one hundred nanometers,
the nanoparticulates are commonly used as gene delivery
vehicles [134]. DNA designed to encode FGFs can be
encapsulated within the nanocapsules to form a complex
and then further transfected to the target cells to elicit the
biological functionality of FGFs [135].
When compared to the polymeric compositions, inor-
ganic particulates for growth factor delivery have been
relatively less studied. Recent attention has been given to the
mesoporous silica nanoparticles, which have a large amount
ofmesoporeswithsizesofabout2–10nm[136,137].Growth
factors can be entrapped within the mesopores of the parti-
cles and then delivered into the target tissues or cells. One of
the widely available inorganic materials for gene delivery is
calcium phosphate (CaP) nanoparticles because the calcium
ion can easily bind with negatively charged nucleic acids,
whichthenformsaCaP-DNAcomplex.Intracellulardelivery
of genes that encode FGFs can be implemented using
inorganic nanoparticulate delivery systems [138, 139].
While nano- and microparticulates are easily manipu-
lated to take up growth factors and can be safely imple-
mented into defect sites, the scaﬀolds and hydrogels can
provide 3D matrices for cells to adhere, migrate, populate,
and diﬀerentiate. Therefore, particulates carrying growth
factors are often embedded within the matrices to act as
cell scaﬀolding and produce therapeutic eﬀects [139, 140],
which is an eﬀective method of fully utilizing the roles and
functionsofFGFsincellsandtissuesforregenerativetherapy
and tissue engineering.
6. Tissue-SpeciﬁcApplications
6.1. Skin. FGFs have the biological activity ofstimulating the
proliferationofﬁbroblastsandangiogenesis,whichfacilitates
potential use in skin wound healing. Both FGF1 and FGF2
are known to be highly released by damaged endothelial cells
and macrophages at wound sites, and if FGF2 activity is
blocked, wound angiogenesis is almost completely impaired
[141]. FGF2 is also known to induce scar-free healing [142].
FGF7 and FGF10 play a role in stimulation of the migration
and proliferation of keratinocytes [143].
However, owing to the short half-like of free FGFs, the
use of delivery systems has been proposed. Among the FGFs,
application studies of wound healing and skin regeneration
have primarily been conducted on FGF2. Because acidic
gelatin is highly negatively charged, it can hold FGF2 well
by forming an ionic complex with gelatin. The 2mg freeze-
dried gelatin microspheres were soaked in 20μla q u e o u s
solution of FGF2 (10mg/ml with an isoelectric point 9.6).
While the free-FGF2 administered in vivo (10, 50, and
100μg) to guinea pigs with full-thickness skin defect could
not induce suﬃcient dermal wound healing, gelatin micro-
spheres incorporated with FGF2 greatly accelerated dermal
tissue regeneration [86]. Using a synthetic hydrogel of chi-
tosan, which is photocrosslinkable, FGF2-incorporation and
sustained release were also implemented [87]. The FGF2-
incorporated hydrogel was photocrosslinked and injected
into the skin wound of healing-impaired diabetic (db/db)10 Journal of Tissue Engineering
mice. The involvement of FGF2 within chitosan hydrogel
was shown to greatly improve wound closure in terms
of granulation tissue formation, capillary formation, and
epithelialization of the wounds.
6.2. Blood Vessels. The angiogenesis and blood vessel forma-
tion induced by the treatment of FGFs have been relatively
well studied. The most commonly used carrier systems for
FGFs are natural polymers including gelatin, which can be
prepared to have diﬀerent charge statuses (negative for acidic
and positive for basic gelatin) [122]. Tabata et al. prepared
gelatin hydrogels with diﬀerent water contents and charge
statuses and then incorporated them with FGF2. When the
complex was implanted subcutaneously into mice, the most
signiﬁcant neovascularization was induced in the FGF2-
incorporating acidic gelatin with a low water content. This
was largely due to the eﬀect of released FGF2, which was
manipulated to be sustained and controlled from the gelatin
hydrogel.
A sustained release of FGF2 and its stimulation of
human umbilical vein endothelial cell (HUVEC) growth
were reported using the heparinized collagen matrix [68],
where the heparin was ﬁrst immobilized to collagen, and
FGF2 was then bound to the heparinized collagen because
the FGF2 has a heparin-binding domain. The heparin was
also immobilized onto synthetic polymer PLGA scaﬀold
to allow a high aﬃnity to FGF2. The FGF2 loading was
greatly enhanced, and the release from the heparinized-
PLGA was controllable. When subcutaneously implanted
in vivo, the FGF2-loaded scaﬀold eﬀectively induced blood
vessel formation [88].
Synthetic polymer PLGA microspheres were also used
to incorporate FGF2 and its sustained-release, which was
then combined with alginate porous scaﬀold [89]. When
implanted in the rat peritoneum, the FGF2-PLGA admin-
istered group showed accelerated vascularization, with a 4-
foldincreaseinpenetratingcapillarieswhencomparedtothe
FGF2-free group occurring. This was mainly attributed to
the sustained release of FGF2 from the microcarriers.
6.3. Muscles. Muscle regeneration has also been greatly
controlled by the FGFs which are abundant in regenerating
areas of muscles [144, 145]. FGF6 is of particular interest
because it is muscle speciﬁc and highly upregulated during
muscleregeneration.FGF2wasdemonstratedtopromotethe
recruitment of skeletal muscle satellite cells using a single
myoﬁber culture model [146]. Doukas et al. used a gene
delivery system that encodes FGF2 and FGF6 for the repair
ofskeletalmuscle[147].Speciﬁcally,plasmidandadenovirus
vectors were immobilized in a collagen-gelatin mixture that
was then delivered to muscle wounds. They found early
muscle angiogenic response and subsequent arteriogenesis,
and muscle repair was also greatly enhanced showing
regenerating myotubes with speciﬁc markers expressions.
Although there have been some controversies regarding the
critical role of FGFs in muscle repair [148], it is largely
accepted that their roles in muscle regeneration are closely
related to the revascularization process [149].
6.4. Adipose Tissues. The roles of FGF2 in adipose regenera-
tionarecloselyassociatedwithangiogenesis.Kawaguchietal.
reported the induction of de novo adipogenesis in mouse
subcutis in response to the injection of FGF2-Matrigel mix-
ture [91], which is associated with vascular formation. Addi-
tionally, matrigel matrix containing gelatin microspheres
incorporated with FGF2 was used for the controlled release
of FGF2 and induction of adipogenesis [92]. At 6 weeks after
subcutaneous implantation in mice, the FGF2-incorporating
group showed signiﬁcantly higher formation of adipose
tissue accompanied with angiogenesis when compared to
that treated with free FGF2. The adipogenesis was dose
dependent (0.01, 0.1, and 1μg FGF2) and the best result
was obtained in the 0.1μg FGF2-incorporated group, sug-
gesting that the use of polymer carrier incorporating an
appropriate level of FGF2 provides a tool for adipose tissue
engineering. Gelatin microspheres incorporating FGF2 were
also used in other studies of adipose tissue regeneration [93,
94]. Kimura et al. showed that FGF2-incorporated gelatin
microspheres enabled preadipocytes to diﬀerentiate adipose
tissue formation [93]. They further showed that collagen
scaﬀold containing gelatin-FGF2 microspheres stimulated
adipogenesis in a rabbit fat defect in response to the
treatment of FGF2-complex scaﬀold [94].
6.5.Tendon/Ligament. Followinginjury(∼duringoneweek)
of tendons and ligaments, the level of FGF2 and its
receptors has been shown to increase in vivo, with FGF2
playing a signiﬁcant role in the recruitment of progenitor
cell diﬀerentiation and the repair process [150, 151]. For
applications of human bone marrow stem cells (hBMSCs)
in the repair of tendons and ligaments, the eﬀects of FGF2
on their proliferation and diﬀerentiation were investigated
[3]. Speciﬁcally, when the FGF2 concentration was low
(3ng/ml), the action was positive in terms of triggering
both cell proliferation and expression of genes related to
tendon and ligament tissue. However, treatment with a high
dose (30ng/ml) did not show any beneﬁcial eﬀects on the
hBMSCs. Targeting anterior cruciate ligament (ACL), FGF2
wasincorporatedintoagelatinhydrogelandthenmixedwith
PLA woven fabric [95]. Following implantation of FGF2-
combined materials wrapped with a collagen membrane in
the tibia and femur of rabbit, ACL and bone were both
regenerated with enhanced mechanical strength.
One recent study showed the possibility of tendon
tissue engineering using BMSCs and a delivery system
encapsulating FGF2 within electrospun nanoﬁber that was
combined with silk microﬁber fabric [96]. The behavior
of BMSCs, including their proliferation and tendogenic
diﬀerentiation, was signiﬁcantly promoted upon FGF2-
loaded ﬁbrous scaﬀolds.
6.6. Cartilage. While the diﬀerentiated traits of chondro-
cytes are generally lost during expansion in monolayer
culture, chondrocytes treated with 5ng/ml FGF2 within the
poly(glycolic acid) ﬁbrous scaﬀold and further expanded
(up to 2000 fold) were shown to rediﬀerentiate to recover
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impregnated within collagen sponge (soaked in 80 μg/ml
PBS for 24h at 4◦C) and implanted subcutaneously in nude
mice, the cartilage regeneration was remarkably accelerated
with cartilage tissues that were immature at 2 weeks and
almost mature at 4 weeks [97]. With regard to the mesenchy-
mal stem cells (MSCs), FGF2 have been shown to modulate
cell growth and maintain the undiﬀerentiated state of stem
cells, facilitating the expansion of stem cells [98]. Moreover,
its regulation of chondrogenic diﬀerentiation of bone mar-
rowstemcells(BMSCs)hasbeendemonstrated[153].Chiou
et al. also reported that the treatment of FGF2 in either
BMSCs or adipose stem cells (ASCs) signiﬁcantly enhanced
chondrogenesis [154], where cell proliferation was shown to
increasedose dependently.Speciﬁcally,theyfoundthatFGF2
at lower concentration (10ng/ml) enhanced chondrogenic
diﬀerentiation, while the eﬀect was negated at higher con-
centration (50ng/ml), suggesting that the use of FGF2 at an
appropriate dose is beneﬁcial for cartilage repair [154].
To induce slow release of FGF2 from the scaﬀold, FGF2
was impregnated within gelatin microspheres [99]. While
free FGF2 showed a rapid in vivo clearance (∼3% remained
after 24h), the level of gelatin-impregnated FGF2 remained
approximately 44% and 18% at days 3 and 14, respectively,
suggesting that the gelatin held the FGF2 eﬀectively. The
FGF2-containing gelatin was preadministrated in an ear-
shaped polymer scaﬀold that also contained chondrocytes
for 1 week. When the tissue-engineered construct was
implanted subcutaneously in mice, signiﬁcantly improved
chondrogenic and neovascularization traits were observed,
suggesting the importance of sustained FGF2 release in car-
tilage tissue engineering. To augment the repair of tracheal
stenosis, an animal study in rabbit was also conducted using
biopolymer scaﬀold-chondrocytes containing FGF2 [100].
The results demonstrated greatly enhanced chondrogenesis
withcartilageaccumulationintheengineeredtrachealwallat
three months after implantation. The combinatory approach
of FGF2 with polymer scaﬀo l dw a sa l s oc o n d u c t e db yM a
et al., who coated the PLA scaﬀold surface with collagen
and FGF2 [101]. To accomplish this, the PLA surface was
ﬁrst chemically treated to covalently graft collagen molecules
and then physically coated with collagen solution contain-
ing FGF2 [101]. The chondrocytes showed signiﬁcantly
improved proliferation on the FGF2-implemented scaﬀold.
6.7.Bones. PossibleeﬀectsofFGF2onosteogenesisandbone
regeneration have also been reported. Lisignoli et al. cul-
tured BMSCs derived from rats within a hyaluronate-based
polymer scaﬀold with or without FGF2 [102]. They found
that the presence of FGF2 strongly enhanced the expression
of osteogenic markers and mineralization, demonstrating a
possible role in bone regeneration. Tabata et al. studied the
role of FGF2 in a rabbit skull defect model [103]. Gelatin
hydrogel was also used to incorporate FGF2 (100μg) to form
a polyionic complex and function as an eﬀective carrier. At
12 weeks, the implants showed dramatic improvement in
defect closure, bone mineral density, and bone regeneration
in groups treated with varying doses (2 to 200μg) of FGF2-
gelatin when compared to an untreated group.
The improvement of bone cell proliferation and diﬀeren-
tiationbytheFGF2wasalsoobservedinanexperimentusing
hydroxyapatite (HA) porous granules incorporating FGF2
[104]. The FGF2 administrated at 0.25μM to 100mg of HA
granules was shown to remain at approximately 80% after
release for 3 days. Speciﬁcally, the osteoblastic diﬀerentiation
of cells (MC3T3-E1) such as alkaline phosphatase (ALP)
activity and mRNA levels of bone-related genes (osteocalcin,
collagen I and ALP) were shown to be signiﬁcantly up-
regulated by the FGF2 treatment, suggesting that HA also
may preserve the biological activity of FGF2. A recent study
also showed that the in vivo bone formation in rats greatly
improved in response to the use of an appropriate carrier
of FGF2 [105]. Collagen was made into a hybrid membrane
with nanobioactive glass, which was impregnated with
FGF2 (100μg) and then implanted within a rat calvarium
defect. The nanobioactive glass-amended hybrid scaﬀold
greatly enhanced the defect closure and bone formation, and
the FGF2-treated group displayed further improvements,
showing the synergistic eﬀect of FGF2 with a bioactive
inorganic component.
The use of FGF2 in dental implants has also been shown
to inﬂuence the formation of bone around Ti-based metals.
FGF2suspendedinMatrigelwasadministratedtothesurface
of Ti and then implanted in ovariectomized rats [106].
The Matrigel used was shown to prolong the life span of
FGF2 upon sustained release for up to 21 days in vitro.
The implant samples after three months were found to
induce great enhancement in new-bone formation (2-fold)
and mechanical stability (3-fold) on the Matrigel-FGF2-
treated group when compared to groups treated with FGF2
or Matrigel alone.
The treatment of osteochondral complex tissue was
also investigated in vivo using a composite scaﬀold made
of HA/collagen incorporating FGF2 [107]. Either 0.5μg
(50μlf r o m1 0μg/ml) or 5μg( 5 0μl from 100μg/ml) FGF2
was impregnated within the HA/collagen scaﬀold and then
implanted into the osteochondral defect in a rabbit femoral
trochlear groove of the knee. During the periods of implan-
tation through 3 to 24 weeks, the 0.5μg FGF2-treated
scaﬀold group displayed greatly enhanced bone regeneration
and satisfactory cartilage regeneration, suggesting that the
HA/collagen composite is a good candidate for delivering
FGF2 during the regeneration of osteochondral defect.
Whiletherehasbeensomeconsensusregardingimprove-
ment of the proliferative potential of osteoblasts, some
adverse eﬀects of FGF2 on the osteogenic diﬀerentiation and
mineralization have also been identiﬁed. Bosetti et al. inves-
tigated the inﬂuence of diﬀerent FGFs (FGF2, FGF4, and
FGF6) on the behavior of human primary osteoblasts [155].
They demonstrated that all FGFs treated in culture medium
at 0.7μM induced osteoblast proliferation but inhibited ALP
activity and mineralization. However, when Vitamin D was
co-administrated with FGFs, the ALP and mineralization
were greatly enhanced, suggesting the combinatory use of
FGFs with other mineralizing agents for bone induction
andbone tissue engineering. Coadministration ofFGF2with
melatonin to the Ti implants showed promotion of osseoin-
tegration during 4 weeks of implantation in rat tibia [108].12 Journal of Tissue Engineering
Apart from the use of FGF2, which has been the
most widely studied, FGF1 was also shown to stimulate
angiogenesis as well as osteogenesis in vitro [81]. FGF1 was
entrapped within the HA-ﬁbrin composite scaﬀold, which
was further implanted in rats subcutaneously. At 2 and 4
weeks postimplantation, the FGF1-containing scaﬀolds was
found to stimulate angiogenesis with blood vessel formation
and the expression of osteogenic markers (osteopontin and
osteocalcin), suggesting that HA-ﬁbrin scaﬀold incorporat-
ing FGF1 is eﬀective for bone repair.
6.8. Dental Tissues. Many dental applications of FGFs are
found in periodontal regeneration [100–103]. Additionally,
periodontal ligament tissue has been shown to be regener-
ated by the action of FGF2 contained in a gelatin carrier
[109]. Tan et al. reported that a periodontal defect in
dogs could be signiﬁcantly regenerated by treatment with
MSCs that were transfected with FGF2 [156]. At eight
weeks after implantation in nonhuman primates, the FGF2-
gelatin group showed signiﬁcant regeneration of periodontal
tissues in a dose-dependent manner [157]. Shirakata et
al. demonstrated that treatment with FGF2 induced the
promotion of periodontal healing in two-wall intrabony
defectsindogs,suggestingthattheywereapossiblecandidate
for replacement of the established benchmarks enamel
matrixderivativeorplatelet-derivedgrowthfactorcombined
tricalcium phosphate [110].
6.9. Nerves. As one of the neurotrophic factors, FGFs have
been shown to enhance the in vitro survival and neurite
extensionofvarioustypesofneuronsaswellasinvivowound
healing and neuronal functions.
FGF2 is known to exist at the blood-brain barrier in
matrix-bound and soluble form, and it is produced by astro-
cytes and has autocrine eﬀects on astrocytes proliferation
and stellation [158]. When compared to the soluble form,
FGF2 bound to matrices has improved half life [159], and its
eﬀects on astrocytes can be potentiated [160, 161]. Delgado-
Riveraetal.covalentlylinkedFGF2ontoananoﬁberpolymer
scaﬀold and observed signiﬁcant autocrine expression of
FGF2 and the modulation of astrocytes-neuron interactions,
suggestingtheutilityofthesysteminnerveinjuryanddisease
[5].
For the repair of spinal cord injury (SCI), Marquet et
al. developed a porous PLA modiﬁed with copolymer and
combined with ﬁbrin glue containing FGF2 and found that
the scaﬀold allowed cell migration and angiogenesis in the
transected spinal cord of rats, suggesting the potential for the
use of the system for SCI, although more clear examination
and functional studies must be conducted to conﬁrm these
ﬁndings [112]. Due to the diﬃculty of the proteins in
penetrating the blood-spinal cord barrier, a local delivery
system consisting of poly(ethylene glycol)-modiﬁed FGF2
andusinganintrathecaldeliveryhasrecentlybeendeveloped
by Kang et al. [113]. The in vivo distribution of FGF2 in
the spinal cord tissue was greatly enhanced. Baumann et
al. also developed a polymer nanocomposite hydrogel FGF1
that has also been shown to have neuroprotective functions
in the repair of SCI. Tsai et al. demonstrated that rat SCI
treated with FGF1 showed signiﬁcant functional recovery
[162]. They also used a synthetic polymer and hydrogel
of ﬁbrin or collagen to carry growth factors such as FGF1
and NT-3, and showed that FGF1 involvement signiﬁcantly
improved the axonal regeneration of vestibular neurons
[111].
For the peripheral nerve regeneration, FGF2 was loaded
within a polymer tube channel and implanted in the 15
mm gap of the sciatic nerve [90]. The results revealed the
in vitro sustained release of FGF2 with biological activity,
and in vivo regeneration of nerve cables bridging nerve
stumps. Similar to other tissue applications, anionic gelatin
wasalsousedtoembedFGF2andinducesustainabledelivery
to the intratemporal facial nerve. The results at six weeks
after implantation demonstrated that facial nerve functions
such as facial movements, electrophysiology and histological
morphology, were greatly improved [114].
7. Concluding Remarks
Fibroblast growth factors (FGFs) that signal through FGF
receptors (FGFRs) regulate a wide range of biological
functions, including cell proliferation, survival, migration,
and diﬀerentiation. Among the signal pathways, RAS/MAP
kinaseisknowntobepredominantinthecaseofFGFs.While
the biological functions of FGFs are largely implicated in
many types of cells in vitro through this signaling pathway,
the maintenance of stability and half-life in vivo should
be considered. Biomaterial-based systems, including delivery
carriers of FGFs and scaﬀolds of stem cells regulated by the
FGFs functions, have recently been potentially developed
and shown to have many good results in vivo.F u t u r e
clinical applications of FGFs in the regeneration of tissues,
including skin, muscle, tendon/ligament, bone, tooth, and
nerve tissues will be realized when their biological functions
are maximized by the appropriate use of biomaterials and
stem cells.
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